|
Capacity expansion and upgradation of manufacturing facilities
|
|
Establishment of a new R&D Centre
|
|
Repayment / prepayment of certain outstanding borrowings
|
|
Working capital requirements
|
|
Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia)
|
|
General corporate purposes
|